• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Precipio Secures a short-term $500K Credit Facility

    5/6/24 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PRPO alert in real time by email

    NEW HAVEN, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces it has secured a short-term loan facility of $500K to deal with any delays in cash collections due to the recent cybersecurity attack on Change Healthcare, a healthcare billing company used by a significant part of the healthcare market.

    Many healthcare businesses, including Precipio's Diagnostic Services division, rely on Change Healthcare (CH) to submit bills and collect cash from various payors and insurance companies for the services they provide. CH experienced a widely publicized cybersecurity attack in early 2024 that impacted the daily flow of cash receipts to the company and, as discussed at the shareholders' call on April 1, 2024, has impacted its cash reserves.

    As mentioned on the call, payments from customers of Precipio's Products division are not processed through CH and were not impacted by the cybersecurity event. Additionally, no cybersecurity attack affected Precipio's own IT infrastructure.

    Under the terms of the facility, the company will draw down the first $250K immediately; and can access an additional $250K in a future time, at its discretion. The company can repay any amount of the loan at any time without prepayment penalties; and it will only pay interest on amounts actually borrowed.

    "We are addressing a short-term operational situation with the appropriate financing tool to remedy the problem, and ensure the company maintains adequate operating liquidity," said Ilan Danieli, Precipio's CEO. "We believe this is a short-term situation rather than a material change to the business, and therefore we felt that a loan facility that the company can access and pay back at its discretion is a suitable vehicle. We are committed to the continued path towards profitability, and believe this is a temporary bump in that road."

    About Precipio

    Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio's reach to eradicate misdiagnosis. For more information, please visit www.precipiodx.com.

    Please follow us on LinkedIn, Twitter @PrecipioDx and on Facebook.

    Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, including other financial projections and potential market opportunity, plans and prospects. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management's estimates, beliefs, assumptions and projections. Words such as "could," "may," "expects," "anticipates," "will," "targets," "goals," "projects," "intends," "plans," "believes," "seeks," "estimates," "predicts," and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties Important factors that could affect performance and cause results to differ materially from management's expectations, or could affect the company's ability to achieve its strategic goals, includes factors that are described in the sections entitled "Risk Factors" and "Management's Discussion and Analysis" in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as updated from time to time in the company's Securities and Exchange Commission filings. The company's forward-looking statements in this press release are based on management's current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.



    Inquiries:
    
    [email protected]
    
    +1-203-787-7888 Ext. 523

    Primary Logo

    Get the next $PRPO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $468 worth of shares (20 units at $23.40), increasing direct ownership by 2% to 1,015 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:22:27 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $488 worth of shares (25 units at $19.50), increasing direct ownership by 3% to 995 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:21:46 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $505 worth of shares (31 units at $16.30), increasing direct ownership by 3% to 970 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:19:49 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Andrews Ronald Asbury was granted 568 shares, increasing direct ownership by 4% to 15,796 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:25:16 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Director Cohen David Seth was granted 746 shares, increasing direct ownership by 1% to 53,688 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:24:23 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Director Cossman Jeffrey was granted 597 shares, increasing direct ownership by 4% to 15,340 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:23:26 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precipio Takes Major Steps Toward a Clean Balance Sheet

    NEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major obligation repaid A $1.1 million advance from Change Healthcare ("CHC"), the Company's clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collections shortfalls. In early January 2026, the Company completed its repayment of that advance. Precipio maintains a small loan with the Connecticut Department of Economic and Community Development in the approximate princ

    1/15/26 9:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

    NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio's BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing concordance with two other leading platforms. The study shows clear, positive impacts on patient care alongside substantial improvements in laboratory workflows. Poster presentation of the study abstract, and results discussion are scheduled for Monday December 8th fro

    12/5/25 10:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact

    NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The incident was limited to its file storage server and did not impact any of Precipio's operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company's operations or finances. Upon detecting the activity, the Company immediately initiated its incident response procedures and engaged an external cybersecurity law firm and forensic specialists t

    12/4/25 8:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    SEC Filings

    View All

    SEC Form S-8 filed by Precipio Inc.

    S-8 - Precipio, Inc. (0001043961) (Filer)

    1/26/26 5:08:49 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Inc. filed SEC Form 8-K: Leadership Update

    8-K - Precipio, Inc. (0001043961) (Filer)

    12/29/25 5:00:27 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Precipio Inc.

    10-Q - Precipio, Inc. (0001043961) (Filer)

    11/14/25 4:29:52 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Financials

    Live finance-specific insights

    View All

    Precipio Takes Major Steps Toward a Clean Balance Sheet

    NEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major obligation repaid A $1.1 million advance from Change Healthcare ("CHC"), the Company's clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collections shortfalls. In early January 2026, the Company completed its repayment of that advance. Precipio maintains a small loan with the Connecticut Department of Economic and Community Development in the approximate princ

    1/15/26 9:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting

    NEW HAVEN, Conn., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) will be presenting at ASH the findings of a joint study conducted with scientific collaborators from Memorial Sloan Kettering in New York, evaluating Precipio's BCR::ABL1 assay. The data from a comprehensive study includes 895 patient samples and demonstrates superior performance of the assay, while showing concordance with two other leading platforms. The study shows clear, positive impacts on patient care alongside substantial improvements in laboratory workflows. Poster presentation of the study abstract, and results discussion are scheduled for Monday December 8th fro

    12/5/25 10:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact

    NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The incident was limited to its file storage server and did not impact any of Precipio's operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company's operations or finances. Upon detecting the activity, the Company immediately initiated its incident response procedures and engaged an external cybersecurity law firm and forensic specialists t

    12/4/25 8:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $PRPO
    Leadership Updates

    Live Leadership Updates

    View All

    SEC Form SC 13G filed by Precipio Inc.

    SC 13G - Precipio, Inc. (0001043961) (Subject)

    8/2/24 2:15:53 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

    NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib

    3/21/22 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    89bio Announces Appointment of Kathy LaPorte to its Board of Directors

    SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien

    11/3/21 8:00:00 AM ET
    $BOLT
    $ETNB
    $PRPO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors

    NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f

    3/3/21 11:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials